Strategic partnerships C2Sense is expanding board expertise with notable industry figures such as Dr. Michael Mina, MD, Ph.D., signaling openness to collaboration with healthcare providers and digital health platforms. Leverage connections to explore joint ventures with medical institutions, diagnostics companies, and health IT vendors.

Clinical validation Halo platform has demonstrated sensitivity and specificity in SARS-CoV-2 detection through published proof-of-concept work. Position Halo as a validated sensing solution for rapid diagnostics and health security applications, targeting hospitals, clinics, and point-of-care networks.

Early stage funding Fundraising history includes seed financing from prestigious investors and The Engine, indicating credibility and growth potential. Use funding story to engage strategic investors, grant programs, and government partnerships that support scalable manufacturing and R&D.

Digital olfactory moat As a Tough Tech MIT spinout building a large digital olfactory platform, there is a unique value proposition for authenticity, product viability, and consumer safety. Target consumer packaged goods, pharmaceutical supply chains, and authentication services seeking real-time odor/biomarker analytics.

Sustainable growth With a lean team size and revenue under one million, opportunities exist to upsell scalable sensing solutions, integrated software stacks, and cloud-based analytics that align with MS Azure and collaborative tools already in use. Propose bundled offerings and managed services to accelerate market adoption.